Q-omics provides the consensus-scored CYB5AP2 profile across patient tissues and cancer cell-line models. CYB5AP2 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, CYB5AP2 is differentially expressed in 6, with the highest sampling consensus in BLCA. Additionally, CYB5AP2 RNA expression shows 14,700 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCS, BLCA, and GBM as cancer lineages where CYB5AP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYB5AP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYB5AP2 survival associations across molecular data types. CYB5AP2 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYB5AP2 RNA expression–survival associations across cancer types. High CYB5AP2 expression shows unfavorable associations in ACC, KIRC, LUAD and PRAD, but favorable associations in UCS and CESC. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for CYB5AP2 RNA expression.
This table summarizes CYB5AP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for CYB5AP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYB5AP2 shows lower tumor expression in BLCA, THCA, LUAD and KIRP and higher tumor expression in ESCA and COAD. The BLCA box plot shows higher CYB5AP2 RNA expression in normal versus tumor tissue (log2 FC = −0.205, t-test p = .015).
This table shows molecular features associated with CYB5AP2 in patient tissues and cancer cell lines. In patient samples, CYB5AP2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
